We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » J&J Sees Delays in Coronavirus Vaccine Production as It Approaches Regulatory Finish Line

J&J Sees Delays in Coronavirus Vaccine Production as It Approaches Regulatory Finish Line

January 14, 2021

As Johnson & Johnson (J&J) nears the release of critical phase 3 trial results and potential emergency authorization for its promising COVID-19 vaccine, the company has reportedly hit speedbumps in manufacturing doses.

The company yesterday declined to confirm or deny reports that it is falling behind its goal of manufacturing 12 million shots of the single-dose vaccine by the end of February by as much as two months and may need until April to hit its target, but told FDAnews it believes it will ultimately meet its supply agreements for 2021.

“It is premature to get into the specifics of the supply of our vaccine candidate, as we do not yet have phase 3 data, nor have we filed for or been granted Emergency Use Authorization (EUA),” a J&J spokesperson said. “[We] are confident in our ability to meet our 2021 supply commitments signed with governments, and we expect to share more detail after some of these steps are achieved.”

Operation Warp Speed’s (OWS) chief adviser Moncef Slaoui, who is resigning from the project next month at the Biden administration’s request, appeared to refer to the reported delays Tuesday, saying that OWS anticipates seeing “single-digit million number of doses available in the second half of February.”

“We’re trying to make that number get as close to a double-digit number as possible, and then a larger number in March and a much larger number in April,” he said.

Slaoui, who has previously called the vaccine a potential “game changer,” said that OWS and the J&J “are very clear” that the company will file for EUA by the end of the month after the FDA’s analysis of phase 3 data. He projected that emergency clearance could come in the middle of February. An EUA for J&J’s vaccine would give the U.S. a crucial third inoculation option for COVID-19.

Though the company may be seeing manufacturing hiccups, its viral-vector vaccine, Ad26.COV2.S, offers a huge advantage in that a vaccination requires just one dose. Coupled with the vaccine’s moderate temperature needs — shipping and storage at -4 degrees Fahrenheit — this would simplify distribution and global vaccination efforts.

The U.S. government has a $1 billion advance order in place with the company to make and deliver 100 million doses, with a provision for 200 million more if needed (DID, Aug. 6, 2020). — James Miessler

COVID-19

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

  • 10Feb

    FDA Under the Biden Administration: What’s to Come and What It Will Mean

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • CE mark

    MiRXES Earns CE Mark for COVID-19/Flu Test

  • KitePharma_Logo

    Kite Pharma’s Tecartus Gains UK Recommendation for Lymphoma

  • Eli Lilly logo

    Lilly’s Monoclonal Antibody Could Prevent COVID-19 in the Elderly

  • CE mark

    Fluidigm Gains CE Mark for Saliva-Based Assay for COVID-19

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing